Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections (Q40589724)

21 September 2017

Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections (English)

1 reference

21 September 2017

1 reference

1

Thomas P Monath

1 reference

21 September 2017

11

Farshad Guirakhoo

1 reference

21 September 2017

Karen McCarthy

2

1 reference

21 September 2017

Philip Bedford

3

1 reference

21 September 2017

Casey T Johnson

4

1 reference

21 September 2017

Richard Nichols

5

1 reference

21 September 2017

Sutee Yoksan

6

1 reference

21 September 2017

Ron Marchesani

7

1 reference

21 September 2017

Michael Knauber

8

1 reference

21 September 2017

Keith H Wells

9

1 reference

21 September 2017

Juan Arroyo

10

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

21 September 2017

1 reference

21 September 2017

20

1 reference

21 September 2017

7-8

1 reference

21 September 2017

1004-1018

1 reference

Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis vaccine--a comparison of 1- and 3-month immunization schedules

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

West Nile virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-hu

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Genetic variation of Japanese encephalitis virus in nature

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Yellow fever vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

CIRCULATING VIRUS, INTERFERON AND ANTIBODY AFTER VACCINATION WITH THE 17-D STRAIN OF YELLOW-FEVER VIRUS.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Original antigenic sin in dengue

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Immunological studies with group B arthropod-borne viruses. I. Broadened neutralizing antibody spectrum induced by strain 17D yellow fever vaccine in human subjects previously infected with Japanese encephalitis virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Serological response to Japanese B encephalitis vaccine of children and horses immune to St. Louis virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Hemagglutination with arthropod-borne viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900457-1

7 January 2021

10.1016/S0264-410X(01)00457-1

Identifiers

DOI

1 reference

21 September 2017

1 reference